Our work 1 that was recently published in Journal of Clinical Oncology simply confirmed the prognostic heterogeneity of sporadic desmoid tumors. In this cohort, we were able to distinguish distinct groups with particular forms of evolution. Indeed, as stated in the discussion section, the retrospective nature of this study cannot determine the method of treatment according to risk. However, the findings should help in future prospective studies that take these different prognostic groups into account to clarify the role of surgery (whether its impact on evolution-free duration is greater in low-risk patients or vice versa), the indications for a wait-and-see policy (whether it is more relevant in low-risk patients or vice versa), and the effects of medical treatment before any locoregional treatment is given.
No takes yet. Share an insight, caveat, or question.
Jefford et al. (2012) studied this question.